HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kava Labeling Revisions Adopted By Trade Groups; FDA Issues Advisory

This article was originally published in The Tan Sheet

Executive Summary

Various dietary supplement trade associations adopted revised kava labeling requirements for their member companies following the release of an 1FDA consumer advisory on the botanical

You may also be interested in...

Echinacea Is Leading Natural Remedy In NIH/CDC Survey On CAM Use

Approximately 40% of people who use natural products as complementary and alternative medicine take the botanical echinacea, according to a recent large-scale survey conducted by the National Institutes of Health and Centers for Disease Control & Prevention

Kava fatalities in MMWR

Possibility of hepatic toxicity associated with use of kava products reported in CDC's Nov. 29 Morbidity & Mortality Weekly Report. MMWR summarizes two case reports: the first involves a 45-year-old woman who underwent liver transplantation after being hospitalized for jaundice and hepatitis following regular use of a kava-containing dietary supplement; the second involves a 14-year-old girl diagnosed with scleral icterus and acute hepatitis following a four-month period of semi-regular kava use. FDA issued a consumer advisory on the botanical earlier this year (1"The Tan Sheet" April 1, 2002)...

FDA Intervention In Kava Labeling Suit Sought By Jarrow Formulas

FDA should release an official statement or publish a proposed rule requiring warnings on kava supplements "if available sound science supports such rulemaking," Jarrow Formulas says in an Oct. 4 citizen petition

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts